Oral drugs are designated as orange dots and blue designates the injectable treatments
In Phase 3 TRIUMPH-4 (Eli Lilly, December 11, 2025), the 12 mg arm averaged 28.7% body weight loss at 68 weeks
One sample report involving a patient, provided by Ro, showed a summary of the insurance coverage, supply availability and estimated copay for each drug, including Wegovy, Ozempic, Eli Lilly's weight loss injection Zepbound and compounded semaglutide, the active ingredient in Novo Nordisk's GLP-1s
While a very small number of patients saw minor fluctuations, none experienced serious bleeding or clotting complications
To ease the intensity of any side effects, Camilleri emphasized the importance of starting out at a lower dose or escalating the dosage at a slower rate than what is recommended by the Food and Drug Administration (FDA)
In clinical trials, people lost an average of 17% of their body weight over 64 weeks, with around one in four losing 20% or more